Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

To Accelerate Research on Anti-aging and Age-related Disease, In Light of the Near Future of a Super-aging Society, Notice of Transfer of Hakushindo Pharmaceutical Co., Ltd. Shares

Hakushindo Pharmaceutical Co.,Ltd.
Posted on: 20 Mar 18

Hakushindo Pharmaceutical Co., Ltd. (head office: Shinjuku-ku, Tokyo, CEO Daizo Shimamura) provided research funding to the Project Research Center For Clinical Trials and Preventative Medicine at the Hiroshima University Graduate School of Biomedical & Health Sciences to carry out the world's first clinical study regarding long-term (24 weeks) oral intake of NMN (β-nicotinamide mononucleotide). The name of the trial is: Evaluation of the effects of long-term ingestion of nicotinamide mononucleotide (NMN). The purpose of the trial is to confirm an increase in rejuvenating hormones, activation of mitochondria, and to confirm the emergence of sirtuin genes 1 and 2.
Hakushindo Pharmaceutical has recently transferred all of its shares to Shinkowa Pharmaceutical Co., Ltd. (head office: Chuo-ku, Tokyo, CEO, Megumi Tanaka).

The clinical trial on oral NMN intake is currently underway at the Hiroshima University Graduate School of Biomedical & Health Sciences: Project Research Center For Clinical Trials and Preventative Medicine.
UMIN trial ID: UMIN000025739
http://rctportal.niph.go.jp/en/detail?trial_id=UMIN000025739

The NMN source used in the clinical trial at the Hiroshima University Graduate School of Biomedical & Health Sciences: Project Research Center For Clinical Trials and Preventative Medicine was purchased from Shinkowa Pharmaceutical Co., Ltd., and the completion of Hakushindo Pharmaceutical's defined role in this clinical trial is the reason for the transfer of the company's shares to Shinkowa Pharmaceutical Co., Ltd.

In the future, Hakushindo Pharmaceutical intends to actively carry out new clinical studies of NMN, as well as other related clinical studies.

Company profile
Company name: Hakushindo Pharmaceutical Co., Ltd.
Representative: Daizo Shimamura
Location: Shinjuku-ku, Tokyo
Business description: Health food and cosmetics sales business, clinical research consignment

View source version on businesswire.com: https://www.businesswire.com/news/home/20180320005617/en/

Business Wire
www.businesswire.com

Last updated on: 20/03/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.